Dopamine D1 agonist R-[11C]SKF 82957: Synthesis and in vivo characterization in rats

Nuclear Medicine and Biology

Volumn 26, Issue 5, 1999, Pages 537-542

  Dasilva, Jean N ^a,b   Schwartz, Robert A ^b   Greenwald, Eric R ^b   Lourenco, Celia M ^b   Wilson, Alan A ^a   Houle, Sylvain ^a  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Carbon 11; D1 receptors; High affinity state; PET; R SKF 82957

Indexed keywords

CARBON 11; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR STIMULATING AGENT; RITANSERIN; SKF 82957; SULPIRIDE; UNCLASSIFIED DRUG; BENZAZEPINE DERIVATIVE; CARBON; DOPAMINE RECEPTOR STIMULATING AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN TISSUE; CONTRAST SENSITIVITY; CONTROLLED STUDY; CORPUS STRIATUM; DOSIMETRY; DRUG BINDING; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG STRUCTURE; DRUG SYNTHESIS; IN VIVO STUDY; METHYLATION; NONHUMAN; OLFACTORY BULB; POSITRON EMISSION TOMOGRAPHY; RADIOACTIVITY; RAT; ANIMAL; BIOTRANSFORMATION; BRAIN; CONFORMATION; DRUG POTENTIATION; FEMALE; HUMAN; MALE; METABOLISM; SPRAGUE DAWLEY RAT; STEREOISOMERISM; SYNTHESIS; TISSUE DISTRIBUTION;

ANIMALS; BENZAZEPINES; BIOTRANSFORMATION; BRAIN; CARBON RADIOISOTOPES; DOPAMINE AGONISTS; FEMALE; HUMANS; MALE; MOLECULAR CONFORMATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; STEREOISOMERISM; TISSUE DISTRIBUTION;

EID: 0032586833     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(99)00015-3     Document Type: Article

References (35)

1. Alburges M.E., Narang N., Wamsley J.K. Alterations in the dopaminergic receptor system after chronic administration of cocaine. Synapse. 14:1993;314-323.
2. 2 subtypes of dopamine receptors in rat brain. J. Neurosci. 6:1986;3177-3188.
3. Clark D., White F.J. Review D1 dopamine receptor - The search for a function: A critical evaluation of the D1/D2 dopamine receptor classification and its functional implications . Synapse. 1:1987;347-388.
4. 11C]SKF 82957 as potential PET radioligands. Appl. Radiat. Isot. 47:1996;279-284.
5. 11C] SKF 82957 in rat brain Two dopamine D-1 receptor agonist ligands . Life Sci. 58:1996;1661-1670.
6. 3H]SKF 38393, in the rat brain and spinal cord. Comparison with the distribution of D2 dopamine receptors. Neuroscience. 19:1986;125-137.
7. Eve I.S. A review of the physiology of the gastrointestinal tract in relation to radiation doses from radioactive materials. Health Phys. 12:1966;131-161.
8. Gnanalingham K.K., Hunter A.J., Jenner P., Marsden C.D. Stimulation of adenylate cyclase activity by benzazepine D-1 dopamine agonists with varying efficacies in the 6-hydroxydopamine lesioned rat - Relationship to circling behaviour. Biochem. Pharmacol. 49:1995;1185-1193.
9. Guttman M. Dopamine receptors in Parkinson's disease. Neurol. Clin. 10:1992;377-386.
10. 2-Dopamine receptor specific brain uptake of carbon-11-labeled YM-09151-2. J. Nucl. Med. 30:1989;515-522.
11. Hess E.J., Bracha H.S., Kleinman J.E., Creese I. Dopamine receptor subtype imbalance in schizophrenia. Life Sci. 40:1987;1487-1497.
12. Kaiser C., Dandridge P.A., Garvey E., Hahn R.A., Sarau H.M., Setler P.E., Bass L.S., Clardy J. Absolute stereochemistry and dopaminergic activity of enantiomers of 2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine. J. Med. Chem. 25:1982;697-703.
13. Kebabian J.W., Calne D.B. Multiple receptors for dopamine. Nature. 277:1979;93-96.
14. 1 rat somatomammotrophic cells. J. Neurochem. 64:1995;2118-2124.
15. 3H-antagonists Evidence for the presence of high and low affinity agonist-binding states . Mol. Pharmacol. 27:1985;171-183.
16. 2 antagonist . Mol. Pharmacol. 27:1985;600-611.
17. Loevinger B., Budinger T., Watson E. MIRD primer for absorbed dose calculations. 1988;The Society of Nuclear Medicine, New York.
18. 1 receptors in schizophrenia. Eur. J. Pharmacol. 223:1993;175-176.
19. 1 dopamine receptor function in rat nucleus accumbens and striatum. Brain Res. 573:1992;331-335.
20. Neumeyer J.L., Baindur N., Niznik H.B., Guan H.C., Seeman P. ( ± )-3-Allyl-6-bromo-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepin, a new high-affinity D1 dopamine receptor ligand Synthesis and structure-activity relationship . J. Med. Chem. 34:1991;3366-3371.
21. Neumeyer J.L., Kula N.S., Baldessarini R.J., Baindur N. Stereoisomeric probes for the D1 dopamine receptor Synthesis and characterization of R-(+) and S-(-)enantiomers of 3-allyl-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine and its 6-bromo analogue . J. Med. Chem. 35:1992;1466-1471.
22. Pfeiffer F.R., Wilson J.W., Weinstock J., Kuo G.Y., Chambers P.A., Holden K.G., Hahn R.A., Wardell J.R., Tobia A.J., Setler P.E., Sarau H.M. Dopaminergic activity of substituted 6-chloro-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines. J. Med. Chem. 25:1982;352-358.
23. Rinne J.O., Laihinen A., Nagren K., Bergman J., Solin O., Haaparanta M., Ruotsalainen U., Rinne U.K. PET demonstrates different behaviour of striatal dopamine D-1 and D-2 receptors in early Parkinson's disease. J. Neurosci. Res. 27:1990;494-499.
24. Rubinstein M., Muschietti J.P., Gershanik O., Flawia M.M., Stefano F.J.E. Adaptative mechanisms of striatal D1 and D2 dopamine receptors in response to a prolonged reserpine treatment in mice. J. Pharmacol. Exp. Ther. 252:1990;810-816.
25. 3H]SCH 23390. Brain Res. 375:1986;291-301.
26. Sedvall C.G., Farde L., Hall H., Halldin C., Karlsson P., Brene S., Lindefors N., Persson H., Chipkin R.E., Ehrlich M., Greengard P. Ligand selection for PET studies of D1 dopamine receptors. Relationship between distribution of binding sites and mRNA for DAARPP32 in the human brain. Clin. Neuropharmacol. 15S:1992;466-467.
27. 11C-SCH 39166, a selective ligand for visualization of dopamine-D1 receptor binding in the monkey brain using PET. Psychopharmacology. 103:1991;150-153.
28. Seeman P., Bzowej N.H., Guan H.C., Bergeron C., Reynolds G.P., Bird E.D., Riederer P., Jellinger K., Tourtellotte W.W. Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. Neuropsychopharmacology. 1:1987;5-15.
29. Seeman P., Grigoriadis D. Dopamine receptors in brain and periphery. Neurochem. Int. 10:1987;1-25.
30. Shinotoh H., Inoue O., Hirayama K., Aotsuka A., Asahina M., Suhara T., Yamazaki T., Tateno Y. Dopamine D1 receptors in Parkinson's disease and striatonigral degeneration A positron emission tomography study . J. Neurol. Neurosurg. Psychiatry. 56:1993;467-472.
31. Sidhu A. Solubilization and reconstitution of the D-1 dopamine receptor Potentiation of the agonist high-affinity state of the receptor . Biochemistry. 27:1988;8768-8776.
32. Stabin M.G. MIRDOSE Personal computer software for internal dose assessment in nuclear medicine . J. Nucl. Med. 37:1996;538-546.
33. Undie A.S., Weinstock J., Sarau H.M., Friedman E. Evidence for a distinct D1-like dopamine receptor that couples to activation of phosphoinositide metabolism in brain. J. Neurochem. 62:1994;2045-2048.
34. Waddington J.L., O'Boyle K.M. Drugs acting on brain dopamine receptors A conceptual re-evaluation five years after the first selective D-1 antagonist . Pharmacol. Ther. 43:1989;1-52.
35. Woolverton W.L., Johnson K.M. Neurobiology of cocaine abuse. Trends Pharmacol. Sci. 13:1992;193-200.